This podcast examines Verona Pharma's ensifentrine, a drug for Chronic Obstructive Pulmonary Disease (COPD), as a case study for AI-driven drug development. It highlights how the company's strategic choices, from the drug's unique "Goldilocks" molecular profile to its targeted delivery method, broad clinical trial design, and niche commercial strategy, led to its successful FDA approval and a multi-billion dollar acquisition. The podcast then details how AI can replicate and enhance these successes across various stages, including molecule design, patient stratification, clinical trial optimization, and commercial strategy, offering a blueprint for future AI-powered pharmaceutical ventures. Produced by Dr. Jake Chen.